Press release
aprimeo diagnostics GmbH & Co. KG starts distribution of the new molecular diagnostics platform Vivalytic from Bosch
R-Biopharm AG, a biotechnological company active in the fields of clinical diagnostics and food & feed analysis, began its partnership on March 1st 2018 with Bosch Healthcare Solutions with the goal of developing, manufacturing and commercializing molecular diagnostic assays for the new Vivalytic platform.Today R-Biopharm AG announced that aprimeo diagnostics GmbH & Co. KG, a R-Biopharm AG company, will execute all activities regarding the commercialization of the Vivalytic platform in several European countries.
“We are very proud and convinced that aprimeo diagnostics will successfully establish the new Vivalytic platform and its assays in the highly competitive Point-of-Care market”, stated Christian Dreher, CEO of R-Biopharm. “Its team of experienced business developers in combination with R-Biopharms product development and manufacturing expertise will enable a successful roll out of this new molecular diagnostic platform providing urgently needed molecular assays for that important market segment.”
“It’s a great honor to be part of a new era in the Point-of-Care market and we are very committed”, said Frank Apostel, Ph.D., Managing Director and Partner of aprimeo diagnostics, former Vice President Business Development & Companion Diagnostic at R-Biopharm AG. “Combining the exceptional benefits of the Vivalytic platform with a broad range of assay applications enables healthcare professionals to make critical decisions improving patients’ care earlier and more accurately than before.”
aprimeo diagnostics GmbH & Co. KG will distribute the Vivalytic platform and its diagnostic assays in Germany, Austria, Switzerland, BeNeLux, France and all Nordic countries starting in the third quarter of 2019.
Vivalytic is a universal platform for molecular diagnostics developed by Bosch Healthcare Solutions GmbH which is a wholly owned subsidiary of Robert Bosch GmbH. It enables various laboratory tests to be performed swiftly and in a fully automated manner. The platform unites a wide spectrum of tests on one device and is open for tests from various providers. This enables the portfolio of available tests to grow continuously. Vivalytic is an all-in-one solution that supports the most widespread laboratory test procedures of molecular diagnostics, uniquely integrating all these procedures in a single system.
R-Biopharm AG
Thomas Hansner, Ph.D.
Director Marketing & Market Access
An der neuen Bergstraße 17
642697 Darmstadt
Germany
Phone: +49 (0)6151 8102-0
Mail: info@r-biopharm.de
aprimeo diagnostics GmbH & Co. KG
Frank Apostel, Ph.D.
Managing Director & Partner
Reißstraße 1a
64319 Pfungstadt
Germany
Phone: +49 (0)6151 800238-50
Mail: media@aprimeo.com
About R-Biopharm
R-Biopharm AG (Darmstadt, Germany) is a globally active biotechnology company and a leading provider of reliable test systems for clinical diagnostics, companion diagnostics and for analyzing human food and animal feedstuffs. Since 1988, R-Biopharm has been developing innovative products characterized by top quality, reliability and efficiency. A strong sense of responsibility, long-standing experience and a network of more than twenty affiliated companies and subsidiaries in Europe, the US, Brazil,Latin America, China, India and Australia, as well as more than 120 distribution partners, make R-Biopharm a prime partner for clients from retail, industry and public institutions looking for answers and solutions for current and future analytical challenges.
About aprimeo diagnostics
aprimeo diagnostics GmbH & Co. KG is a R-Biopharm AG company, focused on the distribution of innovative, next-level diagnostic solutions. R-Biopharm´s partnership with Bosch Healthcare Solutions enables aprimeo diagnostics to provide the innovative molecular diagnostic platform Vivalytic to healthcare professionals, making it possible for them to take better decisions on therapy for their patients each and every day.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release aprimeo diagnostics GmbH & Co. KG starts distribution of the new molecular diagnostics platform Vivalytic from Bosch here
News-ID: 1795008 • Views: …
More Releases for Vivalytic
Multiplex Molecular Diagnostics Market Trends and Will Generate New Growth Oppor …
Multiplex Molecular Diagnostics Market: Outlook
The multiplex molecular diagnostics market may observe a paradigm shift in the growth rate across the forecast period of 2020-2030 due to the growing threat of the novel coronavirus pandemic. The need for effective testing to contain the spread of COVID-19 is on top priority across the globe. Various researchers, scientists, and pharma companies are coming up with novel testing methods for rapid diagnosis. The multiplex…
Car Temperature Sensor Market Strategies and Insight driven transformation 2019- …
Car Temperature Sensor market, delivering a must-read report for industry stakeholders wanting to understand the strategic landscape of this burgeoning sector. Reader will find an in-depth analysis of the market and how it will impact existing traditional markets, as well as insights into future development and opportunities across the globe.
The report provides information about gross profit, revenue, business distribution, the share of the market, and etc. Along with the major…
Molecular Diagnostics Market Analysis 2025 With Industry Players Like: bioMérie …
The key players of the Molecular diagnostics market are making moves like product launches, joint ventures, developments, merges and accusations which is affecting the Molecular diagnostics market and molecular Industry as a whole and also affecting the sales, import, export, revenue and CAGR values. The global Molecular diagnostics market report also contains the drivers and restrains for the Molecular diagnostics market that are derived from SOWT analysis, and also shows…
Molecular Diagnostics Market Comprehensive Study By 2018 to 2025: Agilent Techno …
Company profiles may be quite helpful for creating any revenue, import, export and consumption connected choices within the molecular diagnostics market in chemical business. During this molecular diagnostics market report varied definitions and classification of the business, applications of the business, makers, sourcing strategy and chain structure ar given. The market report additionally provides associate in nursing analytical assessment of the prime challenges round-faced by molecular diagnostics market presently and…
Molecular Diagnostics Market Analysis 2018, Revenue, Share, Size and Global Play …
The Molecular Diagnostics Market report contains data for historic year 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025. The global market is expected to reach USD 13.9 billion by 2025, from USD 7.1 billion in 2017 growing at a CAGR of 8.8% during the forecast period of 2018 to 2025. The clinical uses of molecular diagnostics can be found in no less…
Molecular Diagnostics Market Is Growing In Infectious Diseases Industry With Ana …
Both, top-down and base up approaches were utilized to approve the measure of the worldwide molecular diagnostics market and gauge the extent of different other ward submarkets. Significant players in the market were distinguished through auxiliary research, and their market nearness was contemplated through essential and optional research. Auxiliary sources incorporate yearly reports, official statements, and financial specialist introductions of organizations; white papers; restorative diaries; guaranteed distributions; articles from perceived…
